Exenatide vs Eloralintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Byetta, Bydureon
Exenatide is the original GLP-1 receptor agonist and it came from an unlikely source: the saliva of the Gila monster, a venomous desert lizard. It is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human GLP-1, sold as the twice-daily Byetta (FDA-approved 2005) and the once-weekly Bydureon. It was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy.
Also: GSBR-1290, Structure GSBR-1290
Eloralintide (Eli Lilly code LY3841136) is an investigational, long-acting, selective amylin receptor agonist given as a once-weekly subcutaneous injection for obesity. Amylin is the satiety hormone your pancreas releases alongside insulin, and eloralintide is built to mimic it without the gut side effects that sink most appetite drugs. It is not approved anywhere yet, but it has cleared Phase 1 and a 263-person Phase 2 trial with weight loss up to roughly 20 percent, and Lilly has said it is moving into Phase 3.
Key Comparison Insights
- Exenatide is FDA approved, while Eloralintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Exenatide has stronger research evidence (FDA Approved) compared to Eloralintide (Phase 2 Clinical Trial).
Detailed Comparison
| Attribute | Exenatide | Eloralintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Exenatide binds and activates the GLP-1 receptor, triggering glucose-dependent insulin secretion, suppressing excess glucagon, slowing gastric emptying, and increasing satiety. The reason a lizard peptide beat human GLP-1 to market is durability: native GLP-1 is chewed up by the DPP-4 enzyme within about two minutes, while exendin-4 resists that enzyme and circulates with a half-life of roughly 2.4 hours. Endocrinologist John Eng isolated the peptide in the early 1990s after noting the Gila monster could go long stretches without eating while keeping blood sugar stable. The once-weekly Bydureon formulation traps the peptide in slowly dissolving polymer microspheres so a single injection releases drug over days. | Amylin (also called IAPP) is a hormone co-secreted with insulin after you eat, and it tells your brain you are full and slows how fast your stomach empties. Eloralintide is engineered to selectively switch on the amylin receptor, which is the calcitonin receptor paired with a receptor-activity-modifying protein (RAMP), in appetite-control regions of the brainstem and hypothalamus. The result is reduced food intake and earlier satiety. The reason this class is interesting is that, unlike GLP-1 drugs such as semaglutide and tirzepatide, amylin agonists seem to drive weight loss with much less nausea and vomiting, which is what the eloralintide trials reported. Whether it preserves more lean mass than GLP-1 drugs is a real hypothesis being tested, not a settled fact. |
| Common Dosing | 5-10 mcg twice daily or 2 mg weekly Twice daily (IR) or once weekly (ER) | 120-240mg once daily (oral) Once daily |
| Administration | Subcutaneous injection | Oral tablet |
| Typical Duration | Long-term / chronic use | 36 weeks in Phase 2 trials |
| Best Time to Take | Before bed or morning (fasted) | - |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Exenatide is a long-approved drug with a deep human trial record, not an experimental compound. Its development is well documented in the peer-reviewed literature, including a 2012 review in Regulatory Peptides tracing it from Gila monster venom to an approved antidiabetic. In type 2 diabetes trials it lowered HbA1c and produced modest weight loss, with nausea being the most common side effect, usually fading over time. The EXSCEL cardiovascular outcomes trial found once-weekly exenatide was safe for the heart but did not show a statistically significant reduction in cardiovascular events, which is part of why newer agents like semaglutide and dulaglutide have largely overtaken it. There are rare post-marketing reports of acute pancreatitis, and it is not recommended in severe kidney impairment. Overall, strong human evidence, but now considered an older option in the class. | This is one of the few research peptides on this site with genuinely strong, recent human data. The Phase 1 proof-of-concept study (Eli Lilly, published 2026) randomized 100 adults with obesity across five ascending dose cohorts and reported dose-proportional pharmacokinetics and least-squares mean weight reductions of 2.6 to 11.3 percent by week 12, with notably low gastrointestinal side effects (nausea 8 percent, vomiting 4 percent). In November 2025 Lilly announced topline Phase 2 results in 263 adults with obesity or overweight: at 48 weeks all dose arms beat placebo, with mean weight loss from about 9.5 percent at the lowest dose up to 20.1 percent at 9 mg, versus 0.4 percent on placebo, plus improvements in waist circumference, blood pressure, lipids, and glycemic markers. The most common adverse events were mild-to-moderate nausea and fatigue. The honest caveat: full peer-reviewed Phase 2 data and any head-to-head against tirzepatide are still pending, and there are no long-term safety or cardiovascular outcome results yet because Phase 3 is only just beginning. So the early efficacy signal is impressive, but durability and long-term safety are unproven. |
Frequently Asked Questions: Exenatide vs Eloralintide
What is the difference between Exenatide and Eloralintide?
Exenatide is a weight loss peptide that exenatide is the original glp-1 receptor agonist and it came from an unlikely source: the saliva of the gila monster, a venomous desert lizard. it is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human glp-1, sold as the twice-daily byetta (fda-approved 2005) and the once-weekly bydureon. it was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy. Eloralintide is a weight loss peptide that eloralintide (eli lilly code ly3841136) is an investigational, long-acting, selective amylin receptor agonist given as a once-weekly subcutaneous injection for obesity. amylin is the satiety hormone your pancreas releases alongside insulin, and eloralintide is built to mimic it without the gut side effects that sink most appetite drugs. it is not approved anywhere yet, but it has cleared phase 1 and a 263-person phase 2 trial with weight loss up to roughly 20 percent, and lilly has said it is moving into phase 3. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Exenatide or Eloralintide?
Neither is universally "better" - the choice depends on your specific goals. Exenatide is typically used for weight loss purposes, while Eloralintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Exenatide and Eloralintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Exenatide and Eloralintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.